EFM
NRIX icon

E Fund Management’s Nurix Therapeutics NRIX Stock Holding History

E Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$234K Sell
9,639
-9,157
-49% -$156K 0.01% 429
2026
Q1 		$291K Buy
+18,796
New +$312K 0.01% 400
2025
Q2 		– Sell
-10,288
Closed -$122K – 418
2025
Q1 		$122K Buy
+10,288
New +$172K 0.01% 377

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

E Fund Management's NRIX Position: Q2 2026 in Review

E Fund Management reduced its Nurix Therapeutics (NRIX) stake by 49% in Q2 2026, selling an estimated $156K and leaving 9,639 shares worth $234K. The position accounts for 0.01% of the portfolio, ranked #429.

E Fund Management first reported a position in NRIX in Q1 2025 and has held it in 3 quarters since. The position peaked at $291K in Q1 2026. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • E Fund Management held 9,639 shares of Nurix Therapeutics worth $234K as of Q2 2026.
  • E Fund Management sold 9,157 Nurix Therapeutics shares in Q2 2026, an estimated $156K.
  • Nurix Therapeutics made up 0.01% of E Fund Management's portfolio in Q2 2026, its #429 holding.
  • E Fund Management first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • E Fund Management's Nurix Therapeutics position peaked at $291K in Q1 2026.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.